newsfilter
← Latest News
GlobeNewswire·

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired Levels and Positions